Newsfeeds - Spark Newswire

1 minute read

Portage Biotech Says Sold To SalvaRx An Aggregate Of 10,820 Ordinary Shares Of iOx In Exchange For 1.07M Shares Of Portage; Sellers Have Contingent Right To One-Time Milestone Payment Of $25M In Ordinary Shares Of Portage

Today, 8:55 AM

On July 18, 2022, Portage, SalvaRx and each of the shareholders of iOx Therapeutics Ltd., a private limited company incorporated under the laws of England (“iOx”), listed on Schedule I attached

PRTG

1 minute read

Portage Biotech Says On July 18 Co Entered Into Share Exchange Agreement With SalvaRx

By Benzinga Newsdesk

Today, 8:55 AM

On July 18, 2022, Portage, SalvaRx and each of the shareholders of iOx Therapeutics Ltd., a private limited company incorporated under the laws of England (“iOx”), listed on Schedule I attached thereto

PRTG

1 minute read

Portage Biotech Bolsters Pipeline With Acquisition Of Four Adenosine Pathway-Targeting Candidates

By Vandana Singh

Today, 8:55 AM

Portage Biotech Inc (NASDAQ:PRTG) has agreed to acquire Tarus Therapeutics, a private company developing adenosine receptor antagonists. Under the terms of…

PRTG

4 minute read

Portage Biotech Acquires Tarus Therapeutics In Exchange For 2,425,999 PRTG Shares Along With Assumption Of $3M In Liabilities; Additionally, Payments Of Up To $32M Would Be Triggered Upon Achievement Of Future Milestones

By Bill Haddad

Today, 8:55 AM

Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob Glassman, M.D., Ph.D., director of Tarus and former Venture partner at

PRTG

5 minute read

82 Biggest Movers From Yesterday

By Lisa Levin

Today, 8:55 AM

Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday.

ACLX

5 minute read

79 Biggest Movers From Yesterday

By Lisa Levin

Today, 8:55 AM

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device.

ADTH

2 minute read

Biohaven Provides Update On Phase 3 Clinical Trial Evaluating Troriluzole For Spinocerebellar Ataxia; Co. Reports The Primary Endpoint Did Not Reach Statistical Significance In The Overall SCA Population

By Benzinga Newsdesk

Today, 8:55 AM

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of its investigational therapy, troriluzole, in patients with

BHVN

5 minute read

66 Biggest Movers From Friday

By Lisa Levin

Today, 8:55 AM

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.

AEMD

2 minute read

Portage Biotech Offers Clinical Development Goals For Remainder Of 2022

By Benzinga Newsdesk

Today, 8:55 AM

Clinical Development Goals for the Remainder of 2022 Generate safety and efficacy data on all products currently in clinical trials PORT-2: iNKT agonist to treat melanoma and non-small cell lung cancer (NSCLC)

PRTG